MARKET

RETA

RETA

Reata Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

182.83
-30.84
-14.43%
Pre Market: 184.20 +1.37 +0.75% 08:37 11/13 EST
OPEN
208.58
PREV CLOSE
213.67
HIGH
217.47
LOW
182.14
VOLUME
2.42M
TURNOVER
--
52 WEEK HIGH
217.47
52 WEEK LOW
47.50
MARKET CAP
5.50B
P/E (TTM)
-45.0864
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RETA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RETA News

  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.1h ago
  • Reata Pharmaceuticals (RETA) CEO Warren Huff Discusses Positive Topline Pivotal Year 1 CARDINAL Data (Transcript)
  • Seeking Alpha - Transcript.11h ago
  • Reata Pharmaceuticals: Confusion On The Secondary Endpoint
  • Seeking Alpha - Article.13h ago
  • Reata Pharma Reports 2M Share Common Stock Offering
  • Benzinga.16h ago

More

Industry

Biotechnology & Medical Research
+0.28%
Pharmaceuticals & Medical Research
+0.27%

Hot Stocks

Name
Price
%Change

About RETA

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
More

Webull offers Reata Pharmaceuticals Inc (RETA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.